Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03744975 · ClinicalTrials.gov registry record · Phase 2
PDD in Type 2 Diabetes w/wo Diastolic Dysfunction
A Phase 2 study of Diabetes Mellitus, Type 2 and Diastolic Dysfunction, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT03744975: Completed Phase 2 study of Diabetes Mellitus, Type 2 and Diastolic Dysfunction, sponsored by Mayo Clinic.
NCT03744975 is a Phase 2 study of Diabetes Mellitus, Type 2 and Diastolic Dysfunction that has completed, run by Mayo Clinic. The registered enrollment target is 72 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03744975, a Phase 2 study of Diabetes Mellitus, Type 2 and Diastolic Dysfunction, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will advance the investigator's knowledge of the integrated cardiorenal and humoral physiology in type 2 diabetic patients with and without pre-clinical diastolic dysfunction, and test a novel therapeutic strategy which may prevent a progression to symptomatic Stage C heart failure
Primary Outcome
The change in plasma cGMP levels from baseline to after volume expansion DM with PDD versus non-PDD
Conditions Studied
Interventions
- DRUG Placebos
- DRUG LCZ 696
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2025-08-27 |
| Phase | Phase 2 |
What the finished NCT03744975 record still lists
NCT03744975 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebos is the first listed.
NCT03744975 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03744975 about?
NCT03744975 is a clinical study titled "PDD in Type 2 Diabetes w/wo Diastolic Dysfunction". This study will advance the investigator's knowledge of the integrated cardiorenal and humoral physiology in type 2 diabetic patients with and without pre-clinical diastolic dysfunction, and test a novel therapeutic strategy which may prevent a progression to symptomatic Stage C heart failure
What is the current status of trial NCT03744975?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2018-05-01. Estimated completion is 2025-08-27.
What conditions does trial NCT03744975 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diastolic Dysfunction.
What interventions are being tested in trial NCT03744975?
The interventions under investigation include: Placebos (DRUG), LCZ 696 (DRUG).
Who is sponsoring clinical trial NCT03744975?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03744975 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03744975's enrollment target sits among peer trials
72 227th of 348 higher than 122 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI